e-learning
resources
Barcelona 2010
Sunday, 19.09.2010
Pulmonary circulation III
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Five-year dynamics of main parameters of echocardiography in patients with idiopathic interstitial pneumonias (IIP) receiving active immunosuppressive therapy
A. Rebrov, E. Ponomareva, E. Arkhangelskaya (Saratov, Russian Federation)
Source:
Annual Congress 2010 - Pulmonary circulation III
Session:
Pulmonary circulation III
Session type:
Thematic Poster Session
Number:
1151
Disease area:
Interstitial lung diseases, Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Rebrov, E. Ponomareva, E. Arkhangelskaya (Saratov, Russian Federation). Five-year dynamics of main parameters of echocardiography in patients with idiopathic interstitial pneumonias (IIP) receiving active immunosuppressive therapy. Eur Respir J 2010; 36: Suppl. 54, 1151
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
The definition of pulmonary hypertension: history, practical implications and current controversies
Related content which might interest you:
One year follow-up of patients with idiopathic pulmonary fibrosis treated with immunosuppressive therapy
Source: Annual Congress 2007 - Considerations in the management of idiopathic pulmonary fibrosis and other interstitial lung diseases
Year: 2007
Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study
Source: Eur Respir J 2012; 40: 101-109
Year: 2012
The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate
Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis
Year: 2021
Long-term evaluation of home-based pulmonary rehabilitation in patients with fibrotic idiopathic interstitial pneumonias
Source: ERJ Open Res, 5 (2) 00045-2019; 10.1183/23120541.00045-2019
Year: 2019
Severity before or at the onset of acute exacerbation (AE) can predict the long-term and short-term survival of AE in idiopathic interstitial pneumonias (IIPs)?
Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Year: 2020
Patterns of discontinuation in the long-term RECAP study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights
Year: 2017
Safety and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) receiving commonly used concomitant medications
Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease
Year: 2012
Survival of patients with biopsy-proven usual interstitial pneumonia and nonspecific interstitial pneumonia
Source: Eur Respir J 2002; 19: 1114-1118
Year: 2002
Different characteristics and outcomes of acute exacerbation: comparison between interstitial pneumonia with autoimmune features and lone idiopathic interstitial pneumonia.
Source: International Congress 2018 – Consequences of idiopathic interstitial pneumonias
Year: 2018
Idiopathic interstitial pneumonia (IIP) - optimal timing for initiating treatment
Source: Eur Respir J 2004; 24: Suppl. 48, 535s
Year: 2004
Predictors of survival in idiopathic interstitial pneumonia
Source: Annual Congress 2007 - Considerations in the management of idiopathic pulmonary fibrosis and other interstitial lung diseases
Year: 2007
Efficacy and safety of etanercept in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2006; 28: Suppl. 50, 767s
Year: 2006
Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021
Difference of the clinical characteristics and outcome between interstitial lung disease with dermatomyositis and idiopathic interstitial pneumonia
Source: International Congress 2017 – Lung function testing
Year: 2017
Mortality outcomes in patients with idiopathic pulmonary fibrosis treated with antifibrotics: a real world study
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021
Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia
Source: Eur Respir J 2005; 25: 528-533
Year: 2005
Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Antithrombotics in idiopathic pulmonary fibrosis patients with concomitant antifibrotic therapy: a single centre real world experience
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Vulnerability of fatal infection under steroid treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2002; 20: Suppl. 38, 354s
Year: 2002
Benefit of continued pirfenidone treatment following hospitalisation within the first 6 months of therapy—Ad hoc analysis from three phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept